Friday, June 7, 2013

Importatnt Presentations at ADA 2013

Important Abstracts on GLP-1's

  1. 1033-P/1033 - The Effect of Liraglutide on A1c and Body Weight is Largely Dependent on Diabetes Duration 
  2. 1024-P/1024 - A Novel Long-Acting GLP-1R Agonist, SKL-18287, has Unique Properties Compared to Liraglutide
  3. 1038-P/1038 - Meta-Analysis of GLP-1 Agonist Lixisenatide Use in Patients Insufficiently Controlled with Oral Antidiabetic Drugs Suggests Improved Results in Efficacy, Hypoglycemia & Weight Gain
  4. 1181-P/1181 - GLP-1 Analogs Represent a Novel Treatment Strategy for Alzheimer’s Disease in Patients with Type 2 Diabetes
  5. 2184-P/2184 - A Novel Long-Acting GLP-1R Agonist, SKL-18287, Protects Against Pancreatic β-Cell Deterioration 
  6. 59-LB/059 - HM11260C, a New Generation Long Acting GLP-1R Agonist With a Unique Pharmacokinetic Profile Improves Glucose Control and GI Tolerability: A Phase IIa Clinical Trial in Type 2 Diabetes Mellitus 
  7. 1181-P/1181 - GLP-1 Analogs Represent a Novel Treatment Strategy for Alzheimer’s Disease in Patients with Type 2 Diabetes
  8. 115-OR/0115 - TTP054, a Novel, Orally-Available Glucagon-Like Peptide-1 (GLP-1) Agonist: Results from a 28 Day Study in Subjects with Type 2 Diabetes Mellitus (T2DM)
  9. 67-OR/0067 - Exenatide Once Weekly: Sustained Glycemic and Weight Control Through 3 Years Compared with Insulin Glargine  
  10. 1004-P/1004 - Safety and Efficacy of Dulaglutide vs. Sitagliptin after 104 Weeks in Type 2 Diabetes (AWARD-5)
  11. 1027-P/1027 - Patient-Reported Outcomes with Dulaglutide vs. Metformin (AWARD-3)
  12. 1031-P/1031 - Patient-Reported Outcomes with Dulaglutide, Exenatide, or Placebo (AWARD-1)
  13. 69-OR/0069 - Efficacy and Safety of Dulaglutide vs. Metformin in Type 2 Diabetes (AWARD-3)

Important Abstracts on SGLT2 Inhibitors

  1. 1074-P/1074 - The Sodium Glucose Co-Transporter-2 (SGLT2) Inhibitor Empagliflozin Improves Glycemic Control in Patients with Type 1 Diabetes: A Single-Arm Clinical Trial
  2. 62-LB/062 - Durability of Dapagliflozin vs. Glipizide as Add-On Therapies in T2DM Inadequately Controlled on Metformin: 4-Year Data 
  3. 242-OR/0242 - Plasma Glucose Reduction with the SGLT2 Inhibitor, Dapagliflozin, Improves Insulin Sensitivity and Insulin Secretion in T2DM  
  4. 72-LB/072 - Novel Mechanism of Luseogliflozin, SGLT2 Inhibitor, Induced Beneficial Serum Uric Acid-Lowering Effect

      Important Abstracts on Insulin

      1. 1054-P/1054 - Dose Response to Oral Insulin Capsules in Fasting, Healthy Subjects 
      2.  1021-P/1021 - Expanding the Basal-Plus Regimen: Basal Insulin + Lixisenatide is More Likely to Achieve the Composite Outcome Of Hba1c  < 7%, No Documented Symptomatic Hypoglycemia and No Weight Gain Compared with Basal + Prandial Insulin
      3. 43-LB/043 - New Insulin Glargine Formulation: Glucose Control and Hypoglycemia in People with Type 2 Diabetes Using Basal and Mealtime Insulin (EDITION I)


      Enter your email address:


      Delivered by FeedBurner